AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

SubscribeContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

12 May
AHFS Drug Information logo
AHFS May 2020 Update

This update contains 5 new monographs, 38 revised monographs, 1 discontinued monograph and 3 new MedWatch alerts.

New monographs: Isatuximab-irfc; Rimegepant; Bempedoic Acid; Eptinezumab-jjmr; Cenobamate.

Revised monographs: Sirolimus; Montelukast; Lopinavir and Ritonavir; Nitric Oxide; Pregabalin; Lacosamide; Tocilizumab; Lorcaserin; Sarilumab; Patisiran; Mogamulizumab-kpkc; Doravirine; Doravirine, Lamivudine, and Tenofovir Disoproxil; Inotersen; Moxetumomab Pasudotox-tdfk; Baloxavir; Cladribine; Indomethacin; Ibuprofen; Orphenadrine; Chloroquine; Hydroxychloroquine; Chlorzoxazone; Phytonadione; MethylPREDNISolone; Captopril; Corticosteroids General Statement; Miotics General Statement; Diflunisal; CloZAPine; Cladribine; Gabapentin; Dalteparin; Topiramate; Valsartan; Azithromycin; Zanamivir; Oseltamivir.

Discontinued monographs: Ambenonium.

New MedWatch alerts on the following monographs: Montelukast; Lorcaserin; CloZAPine.

14 Apr
AHFS Drug Information logo
AHFS April 2020 Update

This update contains 8 new monographs and 7 revised monographs.

New monographs: Avapritinib; Ferric Derisomaltose; Antihemophilic Factor (recombinant), Glycopegylated-exei; Teprotumumab-trbw; Tazemetostat; Lasmiditan; Lumateperone; Cefiderocol.

Revised monographs: valGANciclovir; Eravacycline; Omadacycline; Metaxalone; Cyclobenzaprine; Carisoprodol; Methocarbamol.

10 Mar
AHFS Drug Information logo
AHFS March 2020 Update

This update contains 8 new monographs, 15 revised monographs, 2 discontinued monographs and 1 new MedWatch alert.

New monographs: Voxelotor; Givosiran; Enfortumab Vedotin-ejfv; Afamelanotide; Golodirsen; Ubrogepant; Imipenem, Cilastatin, and Relebactam; Fam-Trastuzumab Deruxtecan-nxki

Revised monographs: Dexmedetomidine; Mifepristone; Pregabalin; Sapropterin; Ocrelizumab; Durvalumab; Lutetium Lu 177 Dotatate; Pegvaliase-pqpz; Plazomicin; Iobenguane I 131; Phentolamine; EPINEPHrine; Loperamide; Misoprostol; Gabapentin

Discontinued monographs: daclizumab; dipivefrin

New MedWatch alerts on the following monographs: Pregabalin, Gabapentin

11 Feb
AHFS Drug Information logo
AHFS Drug Information February 2020 Update

This update contains 4 new monographs, 8 revised monographs.

New Monographs: Crizanlizumab-Tmca (Adakveo®); Zanubrutinib (Brukinsa®); Luspatercept–aamt (Reblozyl®); Diroximel Fumarate (Vumerity®)

Revised Monographs: Formoterol; Aliskiren; Fenoldopam; Ketamine; Trifarotene; Minocycline (Topical; Glycopyrrolate; Felbamate

14 Jan
AHFS Drug Information logo
AHFS Jan 2020 Update

This update contains 2 new monographs, 47 revised monographs, and 1 discontinued monograph. 

New monographs: Elexacaftor, Tezacaftor, And Ivacaftor; Minocycline (Topical) 

Revised monographs: Insulin Aspart; Zoledronic Acid; Mycophenolate; Exenatide; Mometasone; Glatiramer; Human Papillomavirus Vaccine; SITagliptin; Febuxostat; Liraglutide; Fingolimod; sAXagliptin; Linagliptin; Tofacitinib; Alogliptin; Canagliflozin; Teriflunomide; Dimethyl Fumarate; Dapagliflozin; Dulaglutide; Empagliflozin; Alemtuzumab; Peginterferon Beta-1a; Lixisenatide; Insulin Degludec; Ocrelizumab; Latanoprostene bunod; Netarsudil mesylate; Ertugliflozin; Angiotensin II; Fremanezumab-vfrm; Galcanezumab-gnlm; Cenegermin-bkbj; Esketamine; Phenytoin; LORazepam; Tamoxifen; hydroCHLOROthiazide; Allopurinol; Benzodiazepines General Statement; Insulins General Statement; Insulin Human; Midazolam; Interferon Beta; metFORMIN; mitoXANTRONE; Raloxifene 

Discontinued monographs: antineoplastic agents GS 

10 Dec
AHFS Drug Information logo
AHFS December 2019 Update

This update contains 3 new monographs, 45 revised monographs, and 1 discontinued monograph. 

New monographs:  

Brolucizumab-dbll; Tenapanor; Trifarotene 

Revised monographs: 

Fosphenytoin; Propofol; Etomidate; Influenza Vaccine Live Intranasal; Eszopiclone; Clevidipine; Rivaroxaban; Influenza Vaccine Recombinant; Apixaban; Pembrolizumab; Evolocumab; Venetoclax; idaruCIZUmab; Brexpiprazole; Cariprazine; Betrixaban; Factor Xa (recombinant), Inactivated-zhzo; Lofexidine; Cannabidiol; Duvelisib; Lorlatinib; Gilteritinib; Prucalopride; Ketamine; Phenytoin; diazePAM; Morphine; Methadone; cloNIDine; Phenylephrine; Pentazocine; fentaNYL; Spironalactone; Opium Preparations; Aspirin; Phenothiazines General Statement; Opiate Agonists General Statement; Anticonvulsants General Statement; Tricyclic Antidepressants General Statement; Antimuscarinics/Antispasmodics General Statement; amLODipine; Zolpidem; Influenza Virus Vaccine Inactivated; Zalepon 

Discontinued monographs:  

Mepenzolate 

View more View all content updates